Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Bronson Healthcare and Acadia Healthcare Break Ground on New Behavioral Health Hospital to Serve Southwest Michigan: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Bronson Healthcare and Acadia Healthcare Break Ground on New Behavioral Health Hospital to Serve Southwest Michigan


Bronson Healthcare and Acadia Healthcare Company today held a virtual groundbreaking ceremony marking the beginning of construction on the new hospital that the two companies are building together

PINC AI™ Applied Sciences (PAS) and Mölnlycke Health Care AB Clinical Trial Aims to Reduce Hospital-Acquired Infections (HAIs): https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
PINC AI™ Applied Sciences (PAS) and Mölnlycke Health Care AB Clinical Trial Aims to Reduce Hospital-Acquired Infections (HAIs)


The PINC AI™ Applied Sciences (PAS) team, a division of PINC AI, the technology and services platform of Premier, Inc. (NASDAQ: PINC), and Mölnlycke, a world-leading medical solutions company

Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting


Novocure (NASDAQ: NVCR) today announced 31 presentations on Tumor Treating Fields (TTFields) will be featured at the Society for Neuro-Oncology (SNO) 2021 Annual Meeting from Nov. 18 to Nov. 21 in

2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma


Novocure (NASDAQ: NVCR) today announced that Dr. David Tran, Chief of the Division of Neuro-Oncology at the McKnight Brain Institute at the University of Florida, has released updated data from the

Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported

Eastlake Behavioral Health Hospital Approved by Chula Vista Planning Commission: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Eastlake Behavioral Health Hospital Approved by Chula Vista Planning Commission


The Chula Vista Planning Commission today approved a new inpatient behavioral health hospital in the Eastlake community of Chula Vista. The Eastlake behavioral health hospital will be operated by a

Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported

Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today

Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

Xencor to Present at Upcoming Investor Conferences: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present at Upcoming Investor Conferences


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

Premier, Inc. to Host Virtual Investor Day on November 17, 2021: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Host Virtual Investor Day on November 17, 2021


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that the company will host its 2021 Virtual Investor Day on Wednesday, November 17, 2021

Premier, Inc. Reports Fiscal-Year 2022 First-Quarter Results: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Reports Fiscal-Year 2022 First-Quarter Results


Premier, Inc. (NASDAQ: PINC) today reported financial results for the fiscal year 2022 first quarter ended September 30, 2021.



"We entered fiscal 2022 with strong momentum and are pleased with

Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today

Pipeline Health System, LLC Partners with Premier Inc.: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Pipeline Health System, LLC Partners with Premier Inc.


Pipeline Health System, LLC (“Pipeline Health”), an independent network of hospitals across California, Texas and Illinois, has selected Premier Inc. (NASDAQ: PINC), a leading technology-enabled

Acadia Healthcare Reports Third Quarter 2021 Results: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Reports Third Quarter 2021 Results


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the third quarter ended September 30, 2021.



Third Quarter 2021 Results



The Company reported revenue of

Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update


Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2021, highlighting commercial strength and strategic investment across clinical, product development and

Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer


Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with

Premier, Inc. and Resilinc Expand Partnership to Enhance Supply Chain Visibility and Sustainability: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. and Resilinc Expand Partnership to Enhance Supply Chain Visibility and Sustainability


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, and Resilinc, the leading supply chain monitoring, mapping and resiliency solution, today announced a new

Premier, Inc. Declares Quarterly Cash Dividend: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Declares Quarterly Cash Dividend


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.20 per share of Class A common

Novocure Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting


Novocure (NASDAQ: NVCR) today announced 15 presentations on Tumor Treating Fields (TTFields) will be featured at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting from Oct. 24

Premier Inc. Releases Inaugural Sustainability Report: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier Inc. Releases Inaugural Sustainability Report


Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today released its inaugural sustainability report detailing companywide initiatives focused on

Acadia Healthcare Names Osei Mevs as Vice President of Government Relations: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Names Osei Mevs as Vice President of Government Relations


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that J.L. Osei Mevs has been named Vice President of Government Relations. In this role, Mevs will oversee the Company’s government

Acadia Healthcare Names David Keys as Chief Development Officer: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Names David Keys as Chief Development Officer


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that David M. Keys, CFA, has been named Chief Development Officer. Keys will focus on mergers & acquisitions, de novo development and

Acadia Healthcare Announces Date for Third Quarter 2021 Earnings Release: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Announces Date for Third Quarter 2021 Earnings Release


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its third quarter 2021 results on Thursday, October 28, 2021, after the close of the market. Acadia will conduct